Eisai submits Marketing Authorisation Variation to EMA for maintenance Alzheimer's treatment
The submission is for a once every four weeks intravenous infusion maintenance dosing regimen for Leqembi (lecanemab), a monoclonal antibody that is currently licensed as a dosing regimen of once every two weeks for early Alzheimer's disease